Literature DB >> 27804190

Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes.

Stéphanie Laugier-Robiolle1, Bruno Vergès2, Maëlle Le Bras3, Elise Gand1, Benjamin Bouillet2, Pierre-Jean Saulnier4, Cédric Le May5, Matthieu Pichelin6, Richard Maréchaud1, Jean-Michel Petit2, Samy Hadjadj1,4,7, Bertrand Cariou6.   

Abstract

Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator of LDL cholesterol metabolism. Little is known, however, about the regulation of PCSK9 in patients with type 1 diabetes (T1D). In the present study, we aimed to determine the relationship between circulating PCSK9 and metabolic variables in T1D. Plasma PCSK9 levels were measured in 195 people with T1D (mean age 38.8 years, mean diabetes duration 17.2 years, mean glycated haemoglobin [HbA1c] 8.3%), who were free of any lipid-lowering agent. Plasma PCSK9 was positively correlated with LDL cholesterol (P = .0007), triglycerides (P = .004), apolipoprotein B (P = .005), HbA1c (P = .003), systolic (P = .003) and diastolic (P = .001) blood pressure and body mass index (0.02). In multivariate analysis, PCSK9 concentration was independently associated with HbA1c (P = .02) and LDL cholesterol (P = .03). After classifying patients according to HbA1c tertile, the correlation between PCSK9 and LDL cholesterol was only observed in the highest tertile (P = .0006; Rho = 0.43), whereas no correlation was found in the lowest and intermediate tertiles. This study suggests that good glycaemic control abolishes the positive relationship between PCSK9 and LDL cholesterol in patients with T1D; however, the underlying molecular mechanisms remain to be established.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  dyslipidaemia; lipid-lowering therapy; type 1 diabetes

Mesh:

Substances:

Year:  2016        PMID: 27804190     DOI: 10.1111/dom.12819

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  4 in total

1.  [The triglyceride-lowering effects of PCSK9 inhibitor differ in patients with different baseline triglyceride levels].

Authors:  Yanren Peng; Guojun Chen; Hua Zheng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-08-30

2.  PCSK9 Is Increased in Youth With Type 1 Diabetes.

Authors:  Amy E Levenson; R Paul Wadwa; Amy S Shah; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; Franziska K Bishop; David M Maahs; Lawrence M Dolan; Sudha B Biddinger
Journal:  Diabetes Care       Date:  2017-06-06       Impact factor: 19.112

3.  Mendelian Randomization Analysis Support Causal Associations of HbA1c with Circulating Triglyceride, Total and Low-density Lipoprotein Cholesterol in a Chinese Population.

Authors:  Xu Jia; Yanan Hou; Min Xu; Zhiyun Zhao; Liping Xuan; Tiange Wang; Mian Li; Yu Xu; Jieli Lu; Yufang Bi; Weiqing Wang; Yuhong Chen
Journal:  Sci Rep       Date:  2019-04-02       Impact factor: 4.379

Review 4.  Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.

Authors:  Simon Glerup; Rainer Schulz; Ulrich Laufs; Klaus-Dieter Schlüter
Journal:  Basic Res Cardiol       Date:  2017-04-24       Impact factor: 17.165

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.